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SUMMARY 
In the present work, the processes of neurodegeneration and radiation-induced brain injury 
and potential neuroprotection are examined in small-animal models. There are a number of 
characteristics in common between neurodegenerative disorders and radiation-related brain injury. 
Both are characterized by progressive neuronal cell death, and motor and cognitive functional 
damage. Neurodegenerative disorders and irradiation are similar in the various associated degrees of 
inflammation. The time course from the initiation of neuronal cell death to the appearance of clinical 
symptoms varies, but a period of decades generally passes before an overwhelming number of 
neurones are affected, which opens up therapeutic possibilities, the aim being to halt further 
neuronal loss. Inflammatory cells often appear in the vicinity of the affected neurones, their presence 
ranging from robust in Alzheimer’s disease (AD) to relatively slight in Parkinson’s disease (PD).  
PD is one of the most common neurodegenerative disorders. Despite recent and continuous 
advances in research, the precise pathomechanism and the unambiguous causes of this disease 
remain unclear. Administration of environmental toxins, e.g. 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), can trigger a similar, but not identical clinical picture, not only in 
humans, but also in rodents. In mice, MPTP, or rather its active metabolite, 1-methyl-4-
phenylpyridinium (MPP+), primarily kills the dopamine (DA)-producing neurones in the substantia 
nigra pars compacta (SNpc), inhibits mitochondrial respiration at complex I and induces oxidative 
stress, which lead to further cell destruction. 
Radiation-induced brain injury often appears after partial or whole brain irradiation and 
involves both anatomic and functional deficits. Until the 1970s, the human brain was thought to be 
highly radioresistant, but later preclinical studies have provided evidence of radiation-induced 
severe impairments in memory, attention and other cognitive dysfunctions which have profound 
effects on the quality of life (QOL). We therefore set out to establish an effective small-animal focal 
brain radiation model for research on brain injuries and to develop new potential therapeutic 
strategies. With this aim, we first developed a precise dose delivery technique for partial brain 
irradiation of 2 rats simultaneously, using a stereotactic frame of the BrainLab system. We later 
described a method which permits precise dose delivery to a definite part of one hemisphere of the 
brain for 6 rats at a time.  
In a search for potential therapeutic approaches, we first tested several inhibitors and 
stimulators of transport proteins localized at the blood-brain barrier (BBB). It was anticipated that 
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stimulation of the multidrug resistance-associated protein 1 (MRP1)- and MRP2-mediated transport 
of glutathione (GSH) conjugates of toxic substances may have slight beneficial effects, whereas 
stimulation of the MRP4-mediated efflux of brain urate, which has important antioxidant potency, 
may worsen the effects of oxidative stress. These data may contribute to a better understanding of 
the pathomechanisms of PD and the relevance of the excitotoxic and neuroinflammatory processes 
in these conditions. 
Thereafter, in the knowledge that the overactivation of excitatory amino acid (EAA) 
receptors plays an important part in the pathomechanism of various neurodegenerative diseases, we 
would have wished to investigate the EAA receptor antagonist kynurenic acid (KYNA) and its novel 
synthetized derivatives. KYNA is an endogenous product of the tryptophan metabolism and may 
serve as a protective agent in neurological disorders. However, we had to exclude the use of KYNA, 
because it is almost unable to pass through the BBB, whereas the newly synthetized analogues can 
readily cross this barrier and exert their complex anti-excitatory activity. Behavioural studies with 
these KYNA amides proved that they do not provoke significant non-specific general side-effects. 
In our advanced partial brain radiation model, the development of morphological and 
functional changes proved to be dose-dependent. To test the spatial learning and memory and to 
detect early functional impairment of the rat brain, the Morris water maze (MWM) task proved to be 
perfect tool. With the aid of magnetic resonance imaging (MRI) screening, we could define the time 
point for histological examinations. The applied model permits accurate dose delivery to a specified 
region in one hemisphere of the brain for 6 rats at a time. Following complex research, a dose of 40 
Gy and a follow-up time of 4 months are suggested for investigations on neuroradiation modifiers. 
Primarily the water-soluble, deacylated phosphatidylcholine derivative L-alpha-
glycerylphosphorylcholine (GPC) improved both the cognitive functions and the learning and 
memory capacity. 
Although the precise pathomechanism of PD and the processes involved in the development and 
progression of radiation-induced cognitive impairment remained unclear, it is clear that there are 
several agents which can modify the course of the disease or mitigate the late effects in preclinical 
models.  
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I. INTRODUCTION 
There may be a considerable number of harmful effects in the background of neuronal 
damage, caused by several different diseases of the nervous system. These damaging factors may be 
traumas, vascular disturbances, physical impacts (e.g. irradiation), toxic effects, inflammation and 
autoimmune, degenerative or tumourous processes.  
Neurodegenerative diseases are severe disorders which primarily affect the nervous system. 
Since the aetiology and precise pathomechanism of these diseases are unknown, the treatment poses 
a great challenge for basic science and clinical investigations. 
Radiation therapy is an important part of the complex management of primary and secondary 
brain tumours. Sadly, the incidence of brain tumours has become more significant over the years, 
and therapeutic strategies to prevent or mitigate radiation-induced cognitive impairment have 
therefore increased in importance. 
There are a number of similarities between neurodegenerative disorders and radiation-
induced brain injury. BBB disruption is one of the major consequences of radiation-induced normal 
tissue injury (Lee et al. 2012) in the central nervous system (CNS) and disruption of the 
neurovascular system has been proved in most neurodegenerative disorders too (Lin et al. 2013; Lee 
& Pienaar 2014). The main mutual feature is that both finally lead to neuronal cell death. The loss of 
neurones is progressive and irreversible, but the temporal appearance of the consequences may 
differ considerably. The time which passes from the initiation of neuronal cell death to the 
appearance of clinical symptoms can vary somewhat, but a period of decades generally passes 
before an overwhelming number of neurones are affected (Bredesen et al. 2006). Inflammation with 
varying degrees of severity can be observed in both cases (Flood et al. 2011; Khandelwal et al. 
2011; Moore et al. 2013). The other important similarity is the impairment of both motor and 
cognitive functions. The functional and morphological changes often coexist. However, their 
distinction can be difficult, and the detection of molecular, cellular and microanatomic changes help 
to unravel the puzzle and facilitate an understanding of the processes in the background of the 
disorders. 
In the present work, we chose to examine PD, a progressive disorder with functional 
abnormalities that lead to dementia. The behavioural changes, loss of memory, and histological and 
cellular disturbances caused by irradiation strongly resemble the changes caused by 
neurodegenerative processes. In both cases, it is essential to make use of small-animal models in 
order to perform complex investigations, including neurofunctional and morphological examinations, 
with potentially neuroprotective, radio-neuroprotective agents. For these reasons, in the present 
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work we investigated these two at first sight not closely related topics, neurodegeneration and 
radiation-induced brain injuries, in light of the fact that neuroinflammation and impairment of the 
BBB may occur in both.  
 
I.1. Parkinson’s disease 
PD, the second most common progressive neurodegenerative disorder after AD (Tanner & 
Goldman 1996), affects approximately 1% of the population older than 65 years (Gibrat et al. 2009). 
It is characterized by a predominance of severe motor dysfunctions and autonomic, psychiatric and 
cognitive disturbances resulting from the loss of DAergic neurones in the SNpc (Hirsch et al. 1988) 
and depletion of DA in the striatum (Savitt et al. 2006; Agid 1991). Despite intensive research, the 
distinct cellular and molecular pathomechanism of PD remains largely unclear. It is well known that 
impairment of the mitochondrial respiratory chain at the level of complex I plays a pivotal role in 
the pathomechanism (Reichmann & Riederer 1989; Schapira et al. 1989). MPTP is highly lipophilic 
and rapidly crosses the BBB, a physical and metabolic barrier which prevents circulating drugs and 
toxins from entering the brain (Markey et al. 1984). MPTP is a neurotoxin precursor to the complex 
I inhibitor MPP+, which selectively destroys the DAergic neurones in the SNpc in human and non-
human primates, with a resulting decline in striatal DA content (Dauer & Przedborski 2003). Indeed, 
administration of MPTP causes permanent symptoms of PD, irreversible neurodegeneration, and in 
mice also results in the appearance of the characteristic biochemical and histological features of the 
human cases (Hallman et al. 1984; Langston et al. 1999). As a consequence, a mouse model of 
MPTP intoxication is the most extensively used animal model of human PD. 
   
I.2. Radiation-induced brain damage  
The incidence of CNS tumours is constantly rising. Radiotherapy is an indispensable part of 
standard complex therapy in the cases of both primary and secondary brain tumours. Radiation-
induced brain injury is a severe, untreatable and irreversible complication of radiation-treated (RT) 
malignant brain tumours and prevents the effective treatment of malignant CNS tumours.  
There is cumulative evidence in the literature that the same factors may play roles in the 
pathomechanism of both multiple sclerosis (MS) and radiation-related injuries of the brain. In both 
cases, axonal damage and necrosis are the main features responsible for the neurological disabilities 
and serious consequences of irradiation. The causes and pathogenesis of axonal damage in MS and 
late radiation injury are still obscure, but there is a growing body of information indicating that both 
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inflammation and demyelination may play a major role in the process (Kreitman and Blanchette 
2004; Na et al. 2013). 
Radiogen necrosis is frequently associated with appreciable functional morbidity and a 
declining QOL in patients treated with brain radiotherapy. In cases of primary CNS tumours and in 
the palliation of metastatic tumours, the brain is one of the most generally irradiated sites for curing. 
Since higher radiation doses to the tumour can elevate local tumour control and improve the entire 
prognosis, radiation dose schemes have changed over the last few decades. Radiation dose 
escalations have been the most extensively applied dose schemes in recent years. With these 
disturbances, severe damage to the parenchyma of the normal brain has become one of the inevitable 
consequences (Tsien et al. 2009; Floyd et al. 2004; Roberge et al. 2009; Beşe et al. 1998). The dose 
which would most probably destroy the tumour can not be delivered by reason of the low radiation 
tolerance of the brain and spinal cord. The emerging new techniques, such as stereotactic 
radiosurgery (Simon et al. 2007), intensity-modulated brachytherapy (Shi et al. 2010), conformal 
and intensity-modulated teletherapy and proton therapy, increase the physical selectivity of the dose 
delivery (Attanasi et al. 2008). However, surrounding normal brain tissue must be included in the 
clinical target volume, because of the potential tumour cell content.  An active neuroprotective agent 
could therefore theoretically increase the therapeutic index, providing the prospective of an 
improved outcome of irradiation or combined chemoradiation. It may lead to ameliorated local 
control and consequently prolonged survival for patients with a high-grade astrocytoma or 
glioblastoma multiforme. The incidence of radiation damage depends on the total dose and the rate 
of delivery (fractionation) (Prasad 2005). Oedema, vasculopathy, infection and chemotherapy 
potentiate radiation injury. Post-irradiation reactions in the CNS are well described as acute, 
subacute and late CNS reactions. Tumours predispose to these normal tissue reactions by the 
oedema and pressure epiphenomena that occur in their environs, and probably by other mechanisms 
associated with tissue breakdown. Radiation-induced delayed brain injury (LDRI) is a well-
documented complication that occurs 4 months to 10 years after radiation therapy (70% of cases 
occur in the first 2 years) (Greene-Schloesser et al. 2013). The incidence of LDRI is 5–37% and 
increases with higher radiation doses. In the lack of effective treatment, LDRI can cause progressive 
deterioration and death; however, the cause of this damage has not been determined. The primary 
mechanism of LDRI involves a vascular endothelial injury or direct damage to the 
oligodendroglia. Cytokines and growth factors are important regulatory proteins controlling the 
growth and differentiation of normal and malignant glial cells, which have been implicated in the 
tissue response to radiation injury. The white matter is affected more than the grey matter (Shi et al. 
2009). The histopathologic examination of post-irradiation specimens demonstrates variable 
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amounts of gliosis, tissue necrosis, calcification, inflammation, and vascular proliferation and 
hyalinization, and also diffuse T-cell infiltration with both CD4+ and CD8+ cells. Infiltrating 
activated macrophages (CD11c+, HLA-DR+) and tumour necrosis factor-alpha and interleukin-6 
immunoreactivity are predominately localized to the macrophages (Kureshi et al. 1994).   
If an effective neuroprotective drug were available, the therapeutic index (the ratio of the 
anti-tumoural effect and the side-effects) could be changed substantially. The histological and 
cellular disturbances caused by irradiation closely resemble the neurodestructive changes and 
neuronal death manifested as a result of neurodegenerative processes. Numerous other studies have 
suggested that neurocognitive deficits and an intellectual decline which severely affect the patient’s 
QOL similarly occur following whole or partial brain irradiation (Roman and Sperduto 1995; 
Greene-Schloesser et al. 2013). Following the incorporation of adjunctive chemoradiation into the 
standard treatment regimen for patients with glioblastoma, many trials have confirmed both 
histopathologically and radiographically up to a 3-fold elevation in the number of treatment-related 
injuries as compared with radiation alone (de Wit et al. 2004; Chamberlain et al. 2007; Brandsma et 
al. 2008). 
I.3. Therapeutic approaches 
I.3.1. ABC transporters and subfamily of MRPs 
Recent investigations have attracted attention to the roles of the dysfunction of the BBB and 
the blood-cerebrospinal fluid barrier (BCSFB) in neurodegenerative disorders. Passage across these 
barriers is modulated by certain transport proteins and pumps. Many of the efflux pumps belong in 
the adenosine triphosphate (ATP)-binding cassette (ABC) transporter superfamily, one of the largest 
and most ancient families of transmembrane proteins. These proteins bind ATP and utilize the 
energy of ATP hydrolysis to perform transporter functions. The classification is based on the 
sequence and organization of their nucleotide binding fold or ATP-binding domain (van Veen & 
Konings 1998). In humans, certain ABC transporters are principal causes of resistance of cancers to 
chemotherapy and are involved in cystic fibrosis and a range of other inherited human diseases. 
The functioning of these transporters moderately influences the bioavailability and 
disposition of many substances (Ayrton & Morgan 2001) by limiting the uptake of drugs or toxins 
into the target cells and also restricting the tissue accumulation of toxic endogenous metabolites 
(Silverman 1999). The ABC transporters can be subdivided into 7 groups, ABCA–G (Borst & 
Elferink 2002). As regards the pathogenesis and treatment of neurological disorders, perhaps the 
most widely studied ABC transporter is P-glycoprotein (P-gp) or human ABCB1 (Lee & Bendayan 
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2004). This is localized on both the luminal (endothelial cells) (Beaulieu et al. 1997) and abluminal 
(astrocyte foot processes) (Golden & Pardridge 1999) sides of the BBB, and the subapical side of 
the choroid plexus epithelia in the BCSFB (Rao et al. 1999). The accumulation of toxic substances 
in the brain may be due to the disruption of P-gp expression at the BBB (Schinkel et al. 1994), 
thereby heightening the risk of neurological disorders, e.g. PD (Drozdzik et al. 2003). However, it 
has been demonstrated that MPP+ is not a P-gp substrate (Staal et al. 2001). 
Increasing attention has recently been paid to the role of MRPs or human ABCCs in 
neurological disorders (Dallas et al. 2006). The data obtained from studies using murine models of 
neurodegenerative diseases, such as AD (Krohn et al. 2011), suggest that MRPs may play an 
important role in the neurodegenerative process too. However, there are only a few arguments in 
favour of the involvement of MRPs in PD pathogenesis (Le Couteur et al. 2001). Abundant data are 
available as regards the localization and function of MRPs in the brain, with some controversies. 
MRP1 has been demonstrated to be expressed on the luminal/abluminal side of the human and 
rodent BBB (Nies et al. 2004; Soontornmalai et al. 2006; Roberts et al. 2008) and on the basolateral 
side of the human and rodent choroid plexus (Soontornmalai et al. 2006; Roberts et al. 2008; 
Nishino et al. 1999). Although MRP1-mediated efflux in the murine BBB is questionable 
(Cisternino et al. 2003), it seems to be fully functional in the BCSFB (Wijnholds et al. 2000). MRP1 
is capable of transporting GSH and oxidized GSH (GSSG) and GSH conjugates of certain 
substances (Zhou et al. 2008). For example, the GSH conjugate of 4-hydroxy-trans-2-nonenal, a 
chemically reactive and prevalent toxic aldehyde, is also transported by MRP1 (Renes et al. 2000), 
which would be an important detoxification mechanism during oxidative stress. However, free GSH 
can also be depleted by MRP1, a process of unclear significance which can be stimulated by 
bioflavonoids, e.g. naringenin (NGN) (Leslie et al. 2003). The function of MRP1 can be inhibited by 
several substances, including silymarin (SIL) (Wu et al. 2005), probenecid (Gollapudi et al. 1997) 
and sulfinpyrazone (SP) (Bakos et al. 2000). Although MRP2 is widely expressed in the luminal 
surface of the capillary endothelium in the porcine and rodent brain (Miller et al. 2000), its 
functional presence in the human brain is equivocal. It has been demonstrated by the use of cDNA 
arrays to be overexpressed in endothelial cells from temporal lobe blood vessels of patients with 
refractory epilepsy (Dombrowski et al. 2001), and polymerase chain reaction analysis showed the 
expression of MRP2 mRNA in perilesional tissue from patients with brain glioma or cerebral 
haemorrhage (Nies et al. 2004), but the MRP2 protein itself could not be detected by 
immunofluorescence microscopy in those perilesional tissues (Nies et al. 2004). The substrates of 
MRP1 and MRP2 show similarity with regard to the transport of GSH, but the affinity of MRP2 for 
GSH conjugates is less than that of MRP1 (Evers et al. 2000). MRP2-mediated transport can also be 
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stimulated by NGN, and interestingly, in contrast with MRP1, SP also stimulates it (Pedersen et al. 
2008). The function of MRP2 can be inhibited by numerous substances, including SIL (Pedersen et 
al. 2008). Although quantitative polymerase chain reaction analysis indicated the brain expression of 
MRP3 mRNA, which shows the highest amino acid sequence resemblance (58%) with MRP1 
(Kiuchi et al. 1998), the protein itself is not synthesized in detectable amounts in the brain (Nies et 
al. 2004). MRP4 and MRP5 isoforms seem to be the major MRP isoforms synthesized in the human 
brain (Nies et al. 2004). MRP4 has been demonstrated to be localized in the luminal surface of the 
human and rodent BBB (Nies et al. 2004; Roberts et al. 2008; Leggas et al. 2004) and on the 
basolateral side of the human and rodent choroid plexus (Roberts et al. 2008; Leggas et al. 2004; 
Choudhuri et al. 2003). Although MRP5 has been reported to be clearly localized to the luminal side 
of the BBB in human brain, it exhibits only a low expression level in the rodent BBB (Roberts et al. 
2008). As regards the BCSFB, MRP5 is mainly localized to the ependymal cells in the rodent brain 
(Roberts et al. 2008). MRP4 and MRP5 have similar substrate specificities and can transport 
molecules involved in cellular signalling, such as cyclic nucleotides (Zhou et al. 2008), while MRP4 
can also transport purine metabolites, such as urate (Van Aubel et al. 2005). Allopurinol (AP), a 
well-known purine analogue and xanthine oxidase inhibitor, has been demonstrated to be an 
allosteric enhancer of MRP4-mediated transport (El-Sheikh et al. 2008), while NGN is capable of 
moderate stimulation of the ATPase activity of the transporter (Wu et al. 2005). SP and SIL are able 
to inhibit both MRP4- and MRP5-mediated transport, to similar extents, while probenecid is a 
considerably more potent inhibitor of MRP5 than of MRP4 (Wu et al. 2005; Reid et al. 2003). 
Probenecid is a widely-used non-selective inhibitor of MRPs and organic anion transporters (Zhou 
et al. 2008; Sugiyama et al. 2001). Probenecid treatment enhances the toxicity of MPTP, which is 
presumably due to the inhibitory effect of probenecid on MPTP transport in the kidney and BBB 
(Lau et al. 1990; Meredith et al. 2008). 
The few available data as regards the role of MRPs in PD led us to investigate the possible roles of 
MRPs in the neurotoxicity of MPTP/MPP+. As there are no specific and selective inhibitors or 
stimulators of MRPs that are available for in vivo and in vitro studies, we applied SIL as an inhibitor 
of MRP1, MRP2, MRP4 and MRP5, NGN as a stimulator of MRP1, MRP2 and MRP4, SP as an 
inhibitor of MRP1, MRP4 and MRP5 and a stimulator of MRP2, and AP as an MRP4 stimulator. 
 
I.3.2. Kynurenic acid analogues 
It is well known that excitotoxicity, which means an extreme high glutamate level in the 
brain, is in the background of numerous neurodegenerative processes. During pathological events, 
neurones are impaired or killed by the overactivation of EAA receptors such as N-methyl-D-
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aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate 
(Olney 1969). The metabolites which can result from the oxidative metabolism of tryptophan and 
mainly the kynurenine pathway can change the excitability of brain tissue. Those compounds which 
inhibit quinolinic acid (QUIN), the glutamate receptor agonist intermediate of the tryptophan 
metabolism, and also free radical-generated effects, might be potentially neuroprotective. KYNA 
exerts an antagonistic effect on the NMDA receptors at the glycine binding site (Kessler et al. 1989) 
thereby decreasing the free radical formation-induced neurotoxic effects of QUIN and its precursor 
3-hydroxy-L-kynurenine, which primarily develop in the neocortex, striatum and hippocampus. 
These regions are the predilection sites of neurodegenerative diseases. L-Kynurenine (L-KYN), the 
precursor of KYNA, and some KYNA derivatives can pass through the BBB. These compounds can 
efficiently inhibit brain injuries following hyperexcitability, and hence in appropriate concentration 
can be neuroprotective, as proved by the attenuation of different noxae (e.g. in cerebral ischaemia, 
pentylenetetrazole-induced epileptic seizure and experimental migraine or Huntington models). 
Those experimental results are likewise very important which suggest that L-KYN and its 
metabolites influence the cerebral blood flow and its vasodilative effect can facilitate 
neuroprotective processes (Bari et al. 2006). Following radiation-stimulated inflammatory reactions 
of the CNS, which restrict the effective therapy of brain tumours, and the selective decline of 
progressive neuronal death caused by microglia degeneration and the impaired circulation of the 
blood supply, KYNA analogues might theoretically be well applicable.  
In recent years, several KYNA derivatives have been developed, among them KYNA amides. One 
of the new analogues, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide 
hydrochloride (KYNA-1), has proved to be neuroprotective in several models. One of our papers 
reports on the synthesis of 10 new KYNA amides (KYNA-1–KYNA-10) and on the effectiveness of 
these molecules as inhibitors of excitatory synaptic transmission in the CA1 region of the 
hippocampus. The molecular structure and functional effects of KYNA-1 are compared with those 
of other KYNA amides. KYNA-1 may be considered a promising candidate for clinical studies. 
 
I.3.3. Potentials in a phosphatidylcholine derivative 
Phosphatidylcholine is a key component of endogenous surface-coating substances and 
biomembranes, and it is well founded that this is the main constituent involved in lipid peroxidation 
and the loss of membrane-forming phospholipid bilayers (Volinsky & Kinunnen 2013). GPC is a 
water-soluble, deacylated phosphatidylcholine derivative which may be hydrolysed to choline and 
can possibly be applied for the resynthesis of phosphatidylcholine (Gallazzini & Burg 2009). 
Interestingly, markedly lower levels of GPC have been reported after experimental haemorrhagic 
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shock, with recovery to the baseline only 24 h later (Scribner et al. 2010). Several lines of research 
suggest that GPC would be efficacious in influencing the inflammatory response. GPC has proved 
effective against loss of the membrane function in CNS injuries (Amenta et al. 1994; Onishchenko 
et al. 2008), and it was previously investigated as a centrally acting parasympathomimetic drug in 
acute cerebrovascular diseases and dementia disorders (Barbagallo Sangiorgi et al. 1994; De Jesus 
Moreno Moreno 2003; Parnetti et al. 2007). After oral administration, GPC has been demonstrated 
to pass through the BBB and reach the CNS, where it is incorporated into the phospholipid fraction 
of the neuronal plasma membrane and microsomes (Tayebati et al. 2011). Brownawell et al. (2011) 
studied the toxicity of GPC in rodents. The acute, subacute and late effects of different GPC doses in 
the range from 100 mg/kg body weight (bw) to 1000 mg/kg bw have been examined in rats. 
Acutely, the lethal dose of intravenously injected GPC was 2000 mg/kg, and the intraperitoneal (i.p.) 
dosing of rats resulted in mortality starting at 1500 mg/kg. In subchronic or chronic studies, doses of 
100 and 300 mg/kg GPC did not modulate the body weight, behaviour, clinical chemistry or 
haematology of rats, and did not produce any signs of general toxicity. 
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II. AIMS 
Our aim was to develop reproducible preclinical models in order to test different approaches and 
compounds which may protect against damage caused by neurotoxic agents.  
We set out to determine tolerability and possible toxic effects of promising neuroprotectors.  
Additionally, we proposed an integrated system of behavioural, histological and molecular 
investigations on correlations of the early and late changes caused by ionizing radiation.  
After establishment of this small-animal model, our goal was to explore the pathomechanism of 
radiation changes and research on potential neuro-radioprotective agents.  
In summary, the aims of our studies were: 
(i) an assessment of the roles of certain MRPs (1, 2, 4 and 5) in the neurotoxicity induced by MPTP; 
(ii) to examine whether KYNA amides exert any behavioural side-effects in the C57B/6 mouse 
strain; 
(iii) to develop a precise dose delivery technique for partial brain irradiation and to set up a small-
animal model of ionizing radiation-induced brain injury; 
(iv) to set up a dose–effect curve of radiosensitivity and to establish the most appropriate dose of 
irradiation for research on radiation modifiers; 
(v) to investigate late effects of radiation-induced brain injuries; and  
(vi) to apply the model to investigate potential radiation-induced brain injury modifiers. 
 
 
 
 
 
 
 
 
 
  
18 
III. MATERIALS AND METHODS 
III.1. Drugs 
NGN, SIL, SP, AP, sesame oil, MPTP, DA hydrochloride, 3,4-dihydroxyphenylacetic acid 
(DOPAC), homovanillic acid (HVA), sodium metabisulphite and sodium octylsulphate were from 
Sigma-Aldrich Hungary Ltd. (Budapest, Hungary). Perchloric acid, disodium 
ethylenediaminetetraacetate (EDTA), sodium dihydrogenphosphate, acetonitrile and phosphoric acid 
were from VWR International Ltd. (Debrecen, Hungary).  
L-KYN sulphate (KYNA-11) was from Sigma-Aldrich Hungary Ltd. (Budapest, Hungary). New 
KYNA amide derivatives (KYNA-1, N-(3-N,N-dimethylaminopropyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride (KYNA-2) and N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride (KYNA-6)) were prepared from KYNA and the appropriate amine by 
using N,N-diisopropylcarbodiimide as coupling reagent.  
GPC was produced by Lipoid GmbH (Ludwigshafen, Germany). 
 
III.2. Behavioural studies 
III.2.1. Open-field 
The spontaneous locomotor and exploration activities were measured by an automated tracking 
system with an activity chamber. The open black box with a dark floor was made of wood. The box 
was connected to a computer which recorded the inquisitive behaviour and locomotor activity of the 
animal. Each animal were placed individually at the centre of the black box (48 x 48 x 40 cm), 
which was equipped with automated infrared photocells for measurements, and allowed to move 
spontaneously for 5 (in the case of mice) or 15 (in the case of rats) minutes. The tests were 
performed at the same time of day so as to minimize changes due to the diurnal rhythm. Between 
sessions, the arena was cleaned with 70% alcohol and dried. The movement signals were analysed 
by Conducta 1.0 (Experimetria Ltd, Budapest, Hungary) software. The analysis resulted in a track 
record; the locomotor activity was expressed as the total distance moved (cm) in a predetermined 
period of time, the times spent in movement and at rest (s), the mean velocity (cm/s), and the 
frequency and duration of rearing. 
In the course of the studies of the behavioural effects of KYNA analogues, the mice were examined 
2 h after the first treatment (acute), and then on the last day (day 9) of treatment (chronic). In this 
case, the ambulation time, the mean velocity, the local time and the number of rearings were 
evaluated. In the other experiments, rats were tested every 2 weeks and the ambulation distance, 
velocity, immobility time and rearing count were assessed. 
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III.2.2. Morris water maze test 
The MWM protocol of Vorhees and Willams (Vorhees and Williams 2006) was used, visuospatial 
cues being provided to guide the animals in tests of hippocampal memory. The MWM consisted of a 
cylindrical white tank with a diameter of 175 cm and a height of 50 cm, containing liquid made 
opaque with a non-toxic white dye. The tank was filled with water up to 32.5 cm and maintained at 
21–24 °C. The pool was divided into four equal quadrants, and a removable transparent Plexiglas 
platform (10 cm in diameter) that could not be seen by the swimming rats was hidden at the centre 
of one of the quadrants, with its top 1 cm below the surface. The platform provided the only escape 
from the water. The position of the platform was constant throughout the 3-day acquisition period. 
Pictures fixed permanently on the surrounding walls served as distal navigation cues to enable the 
rats to locate the platform. The distinctive visual cues remained constant throughout the entire 
course of testing. The first two days were acquisition or training days, and the task was performed 
on the third day. The training period consisted of 4 trials per day with a 5-min inter-trial interval. 
Each trial began with the rat in the pool and ended when the rat found the platform or after 120 s. If 
the animal failed to locate the platform within 120 s, it was guided to the platform manually. Once 
on the platform, the rat was allowed to rest for 10 s. It was then towel-dried and placed in an inter-
trial holding cage where a heating source was provided to maintain the animal’s body temperature 
during the inter-trial interval. During the acquisition phase, measurements were made of the time (s) 
and the path length (cm) taken to locate the platform. This site navigation test was performed once 
before the irradiation and subsequently once in the third and once in the fourth month. 
  
III.3. Animal model of PD 
III.3.1. Animals 
The procedures utilized in this study followed the guidelines of the European Communities Council 
(86/609/ECC) to minimize animal suffering and were approved in advance by the Ethics Committee 
of the Faculty of Medicine, University of Szeged. Six-week-old C57B/6 male mice (weighing 
between 18 and 23 g) were used. The animals were housed in cages (at most 5 per cage) and 
maintained under standard laboratory conditions, with tap water and regular mouse chow available 
ad libitium on a 12 h light-dark cycle, at 21±1 ºC and 50±10% humidity. 
  
III.3.2. Treatments 
Four groups of mice were used in the first 4 experimental set-ups for the assessment of the 4 
substances. The first 2 groups of mice received i.p. injections of SIL (100 mg/kg/day, in a volume of 
5 ml/kg, suspended in sesame oil; n1=8, n2=9), NGN (100 mg/kg/day, in a volume of 5 ml/kg, 
  
20 
suspended in sesame oil; n1=7, n2=7), SP (100 mg/kg/day, in a volume of 5 ml/kg, suspended in 
sesame oil; n1=8, n2=9) or AP (60 mg/kg/day, in a volume of 5 ml/kg, suspended in sesame oil; 
n1=10, n2=10) respectively, once a day, at the same time each day for one week. The second 2 
groups of mice received sesame oil (in a volume of 5 ml/kg; n3=8, n4=8; n3=7, n4=7; n3=8, n4=9; 
n3=6, n4=10) in the same treatment regime. On day 8 of the experiments, 1 h after the regular daily 
injections, the second and fourth groups received i.p. injections of MPTP (15 mg/kg, in a volume of 
5 ml/kg, dissolved in 0.1 M phosphate-buffered saline (PBS)) 5 times at 2 h intervals (total dosage: 
75 mg/kg). The first and third groups received 0.1 M PBS (in a volume of 5 ml/kg) in the same 
treatment regime. From day 9, the 4 substances were further administered once a day for another 
week, with the corresponding control injections, according to the treatment regime detailed above. 
 
III.3.3. Sample preparation 
Eight days after toxin administration (day 16 of the experiment), all the mice were decapitated and 
the brains were rapidly removed and placed on an ice-cooled plate for dissection of the striatum. 
After dissection of both striata from the forebrain block, these were stored at −70 °C until further 
sample processing. In the next step, the striata were weighed and then manually homogenized in an 
ice-cooled solution (250 µl) comprising perchloric acid (7.2 µl; 70% w/w), sodium metabisulphite (1 
µl; 0.1 M), EDTA (1.25 µl; 0.1 M) and distilled water (240.55 µl) for 1 min in a homogenization 
tube. The content of the homogenization tube was washed quantitatively into a polypropylene 
Eppendorf tube with the used solution to give a final volume of 1.5 ml, which was then centrifuged 
at 10,000 g for 15 min at 4 °C. Thereafter, the supernatant was transferred to another polypropylene 
Eppendorf tube and was stored at −70 °C until chromatographic analysis. 
 
III.3.4. Chromatographic conditions 
DA and its metabolites, DOPAC and HVA, were analysed by reversed-phase chromatography, using 
an Agilent 1100 high-performance liquid chromatography (HPLC) system (Agilent Technologies, 
Santa Clara, CA, USA) combined with a Model 105 electrochemical detector (Precision 
Instruments, Marseille, France) under isocratic conditions. In brief, the working potential of the 
detector was set at +750 mV, using a glassy carbon electrode and an Ag/AgCl reference electrode. 
The mobile phase containing sodium dihydrogenphosphate (75 mM), sodium octylsulphate (2.8 
mM) and EDTA (100 µM) was made up with acetonitrile (7% v/v) and the pH was adjusted to 3.0 
with phosphoric acid (85% w/w). The mobile phase was delivered at a rate of 1 ml/min at 40 °C 
onto the reversed-phase column (HR-80 C18, 80×4.6 mm, 3 µm particle size; ESA Biosciences, 
Chelmsford, MA, USA) after passage through a pre-column (Hypersil ODS, 20x2.1 mm, 5 µm 
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particle size; Agilent Technologies, Santa Clara, CA, USA). Ten-microlitre aliquots were injected 
by the autosampler with the cooling module set at 4 °C. The signals captured by the Model 105 
electrochemical detector were converted by an Agilent 35900E dual-channel interface and the 
chromatograms were evaluated by ChemStation Rev.1.10.02 software (Agilent Technologies, Santa 
Clara, CA, USA). 
 
III.4. Study of behavioural effects of some kynurenic acid analogues 
III.4.1. Animals 
Behavioural experiments were carried out on 6-week-old C57B/6 male mice (n=60).  The animals 
were kept under controlled environmental conditions at 22±2 ˚C under a 12-h light-dark cycle. Food 
and water were available ad libitum. The local Animal Ethics Committee had approved all 
experiments. The care and use of the experimental animals were in full accordance with the 
86/609/EEC directive. 
 
III.4.2. Treatment regime 
The mice received i.p. injections of KYNA-1 (200 mg/kg/day, in a volume of 5 ml/kg, dissolved in 
distilled water, the pH of which was adjusted to 6.5 with 1 N NaOH). For comparison, KYNA-2 or 
KYNA-6 in equimolar dosages (likewise in a volume of 
5 ml/kg, dissolved in distilled water, the pH of which was adjusted to 6.5 with 1 N NaOH) or the 
vehicle (0.1 M PBS, in a volume of 5 ml/kg) was administered at the same time each day from 6 
weeks of age. 
In behavioural experiments, the mice were treated once (in acute experiments) or for 9 days (in 
chronic experiments) according to the regime detailed above. 
 
III.5. Small-animal model of irradiation 
III.5.1. Animals 
Experiments were performed on 57 adult Sprague-Dawley (SPRD) male rats, weighing on average 
210 g (range 176–280 g). The animals were housed in a climate-controlled environment (25 °C) 
maintained on a 12 h light/12 h dark cycle and were allowed free access to food and water. All 
experiments were conducted in full accordance with the European Communities Council Directive 
(86/609/EEC) for the Care and Use of Laboratory Animals and were approved by the University 
Animal Research Committee. 
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III.5.2. Dosimetry of small electron field 
In order to verify the dose depth curve, the field profile and the lateral dose fall-off of the 2, 4, 6, 8, 
10 and 12 mm electron collimators, we measured the absorbed dose of a 6 MeV electron beam 
irradiating at a dose rate of 300 monitor units (MU)/min in a water phantom, using a pin-point 
ionization chamber (Canberra Packard Central Europe GmBH, Schwadorf, Austria), and in a solid 
water phantom with a 1 cm build-up layer for film dosimetry (Canberra Packard Central Europe 
GmBH). The graphical representation of the entrance of the treatment beam was aligned with the 
approximate location of the corpus callosum–hippocampus as determined from the pre-existing MRI 
and computed tomography (CT) scan of a rat. Thus, for evaluation of the dose distribution, the 90% 
and 70% isodose levels were superimposed on the image of the skull, aligned with the approximate 
location of the general rat brain structures (Figure 1A). 
 
Figure 1. Dose distribution using a 10 mm diameter beam. The 90% and 70% isodose levels are 
superimposed on the sagittal image of the rat brain (A). The haematoxylin–eosin (H&E) slide of the 
brain at the 70 Gy dose level. Damage caused by the irradiation on the left side localized to a 
defined small brain volume in the high-dose region, without any histopathological aberrations in the 
contralateral hemisphere (B). The sub-panel image right to image B shows the post-irradiation 
brain injury at higher magnification.  
 
III.5.3. Irradiation 
Two prone adult male SPRD rats placed nose-to-nose in the irradiation position, with earpin fixation, 
were imaged in the Emotion 6 CT scanner (Siemens AG, Erlangen Germany) in order to obtain 
three-dimensional (3D) anatomical information for planning of the radiation geometry. Slices (1.25 
mm) were obtained by using the maximum resolution afforded by the scanner. The whole brain, 
eyes, internal ears, corpus callosum and hippocampus on both sides, together with the target volume, 
were delineated in the XIO CMS™ treatment planning system (ELEKTA, Stockholm, Sweden), 
using MRI and the anatomy atlas of the rat brain. A 6 MeV lateral electron beam at a 100 cm 
A B 
50% 
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source-to-skin distance (SSD) was chosen because it has a sharp dose fall-off with depth, confining 
the radiation dose delivery to the defined volume of the hippocampus, including the corpus callosum 
of the ipsilateral hemisphere, while sparing the skin, the eyes, the ears, the cerebellum, the frontal 
lobe and the contralateral half of the brain (Figure 1A, 1B). No build-up bolus was used. The 
planned doses were delivered in a single fraction by means of a linear accelerator (Primus IMRT, 
Siemens, Erlangen, Germany) at a dose rate of 300–900 MU/min, with 6 circular apertures 10 mm 
in diameter, each in a 20 mm thick Newton metal insert placed into the 15 x 15 cm electron 
applicator, to the following groups of animals: 120 Gy (n=3), 110 Gy (n=3), 100 Gy (n=3), 90 Gy 
(n=6), 80 Gy (n=3), 70 Gy (n=6), 60 Gy (n=3), 50 Gy (n=6), 40 Gy (n=12) and sham-irradiated 
(n=12). Immediately prior to irradiation, the animals were anaesthetized with an i.p. injection of 4% 
chloral hydrate (1 ml/100 g Fluka Analytical, Buchs, Switzerland). They were placed 2-by-2, nose-
to-nose, on the 3-storeyed positioning device on the couch of the irradiation unit and their heads 
were aligned individually at the intersection of the beam axis-marking lasers. The light field was 
directed at exactly the middle of the distance between the eye and ear, with the upper edge at the top 
of the skull. An ear plug was inserted into the ipsilateral ear. Pairs of animals were situated on all 3 
storeys. The irradiation dose rate was 300/900 MU/min and de-escalated doses ranging from 120 to 
40 Gy were applied, with 3–12 animals per dose level. The monitor units (3000 MU/10 Gy) used for 
the irradiation were derived from the previous small-field dosimetry. The radiation geometry was 
verified prior to the irradiation, and documented by control imaging on film after the irradiation 
(Figure 2). The animals were first imaged with the 6-hole insert exposed to 6 MeV electrons (50 
MU), after which the insert was removed and a large field (20 x 20 cm) of 6 MeV photons was 
imaged (1.6 MU) to obtain an outline of the skull together with the body landmarks such as the oral 
cavity, ear canals, etc. Sham controls were anaesthetized, but not imaged or irradiated. Following 
treatment, the animals were transferred to their home cages and kept under standard conditions, with 
weekly weight measurements, descriptive behaviour observations and skin detection. 
 
Figure 2. The preparation for irradiation was performed by individual fixation of the rats after 
alignment of reference points under i.p. anaesthesia. Pairs of animals were situated on all 3 storeys 
  
24 
of the positioning device. The radiation geometry was verified prior to the irradiation with the aid of 
the intersection of the beam axis-marking lasers, and documented by control imaging on film after 
the irradiation. 
 
III.5.4. Magnetic resonance imaging  
Sixty rats underwent 72 MRI procedures prior to or 4–19 weeks after irradiation. Randomly selected 
animals from each irradiation dose level were examined by means of 1.5 T MRI (Signa Excide 
HDxT, GE Healthcare, Little Chalfont, Buckinghamshire, UK), using a human head coil with a 
home-made styrofoam holder containing 6 animals under i.p. chloral hydrate (Sigma Aldrich, St 
Louis, MO, USA) anaesthesia. No contrast agent was used for the MRI images. Twelve animals 
underwent 3 MRI examinations, at baseline, at mid-term and prior to histology: coronal-T1 (T1: 
longitudinal relaxation time) 3D ultrafast gradient echo with magnetization preparation [IR-FSPGR], 
field of view [FOV] 17.0 mm2, inversion time [TI] 450 slice thickness [ST]: 1.2 mm), sagittal (3D 
Cube T2, repetition time [Tr] 3000, echo time [TE] 60, FOV: 13 mm2 , TI 450, ST: 1.2 mm, Space 
[Sp]: 0) and coronal T2 (T2: transverse relaxation time) weighted (3D IR-FSPGR; FOV: 13 mm2 , 
ST: 1.2 mm, Sp: 0) images were acquired. The MRI procedure required about 10 min per sequence. 
 
III.5.5. Histopathology 
Rats were anaesthetized with 4% chloral hydrate and perfused transcardially with 0.1 M phosphate 
buffer solution (pH 7.0–7.4) before they were fixed with 4% paraformaldehyde buffer solution (pH 
7.0–7.4) at 4 °C. The brains were dissected out and postfixed in paraformaldehyde for 1 day before 
being embedded in paraffin. Serial 30-µm-thick sections were cut with a vibratome. Sections were 
stained with H&E for histologic evaluation; for the demonstration of demyelination, Luxol fast blue 
staining was used. All analyses were performed blindly, using coded sections. Evaluations were 
carried out with a semiquantitative method, independently by 2 experienced histopathologists. A 
score was awarded for each examined parameter (necrosis, macrophage density, vascularization, 
haemorrhage, reactive gliosis, calcification and demyelination) on a semiquantitative scale of from 1 
to 4 (where 1 represented the normal brain structure). In the case of necrosis, at low magnification 
(optical magnification [OM] 50x): 1: not detected; 2: necrosis detected in <50% of the examined 
field; 3: necrosis detected in 50–100% of the examined field; 4: the necrosis detected was larger than 
the FOV, or affected both hemispheres of the brain. The macrophage density was examined at high 
magnification (OM 400x): 1: no foamy macrophages detected; 2: 1–4 foamy macrophages/high-
power field (HPF); 3: 5–10 macrophages/HPF; 4: >10 macrophages/HPF. Vascularization was 
scored (OM 50x) as 1: no neovascularization detected; 2: newly-formed small, simple capillaries 
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detected around the necrosis; 3: newly-formed capillaries detected around the necrosis, which 
contained variously-sized, but simple capillaries; 4: large, complex capillaries or small capillaries 
seen with endothelial proliferation. Haemorrhage (OM 50x): 1: no haemorrhage detected; 2: 
haemorrhage detected in a single, small focus; 3: haemorrhage seen in multiple small foci, or a 
single, larger focus; 4: extensive multiple haemorrhage detected. Reactive gliosis (OM 200x): 1: no; 
2: mild; 3: moderate; 4: severe reactive gliosis detected in the brain. 
Calcification (OM 50x): 1: no calcification; 2: a single small calcified focus detected; 3: multiple 
small or a single, larger focus detected; 4: extensive, multiple calcifications detected. 
Demyelination (OM 400x): 1: none; 2: mild; 3: moderate demyelination, but fibres detected; 4: 
severe demyelination, with destruction of the fibres. 
 
III.6. Application of GPC in the small-animal model of partial brain irradiation 
III.6.1. Treatment 
A total of 24 adult (6-week-old) male SPRD rats (purchased from the Animal House of the 
University of Szeged) were used in these experiments. The 40 Gy dose level (which was found to be 
appropriate for the detection of brain injury in a reasonable time period) was selected for the 
investigation of neuroprotection. Rats (weighing from 180 to 220 g) were anaesthetized (4% chloral 
hydrate (Fluka Analytical, Buchs, Switzerland), 1 ml/100 g, i.p.) and placed in the prone position, 
using laser alignment. After earpin fixation, they were imaged in the Emotion 6 CT scanner 
(Siemens AG, Erlangen, Germany) in order to plan the radiation geometry. The dosimetry of the 
small electron field and the method of irradiation were the same as previously. The following groups 
of animals participated in the experiment: a sham-irradiated control (CO) group (n=6), an only GPC-
treated (GPC) group (n=6), an RT group (n=6), and a both GPC-treated and irradiated (GPC+RT) 
group (n=6). Beginning from 1 week before the day of irradiation, the rats received GPC (Lipoid 
GmbH, Ludwigshafen, Germany; 50 mg/kg bw, dissolved in 0.5 ml sterile saline, administered by 
gavage) or the vehicle at the same time every second day (on Mondays, Wednesdays and Fridays) 
for 4 months. 
 
III.6.2. Histopathology 
The preparation for and conductance of the histopathology were the same as reported above. 
Sections were analysed under an Axio Imager.Z1 (EC Plan Neofluar 40x/0.75 M27, Freiburg, 
Germany) light microscope, and photomicrographs were taken with AxioCam MR5 camera 
equipment. Digital photos were analysed with the aid of Image-Pro® Plus 6.1 software 
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(MediaCybernetics Inc., Bethesda, MD, USA). All analyses were carried out blindly on coded 
sections by 2 independent histopathologists. The examined parameters and the scoring system were 
not altered. 
 
III.7. Statistical analysis 
All statistical analyses of HPLC measurements were performed with the help of the SPSS Statistics 
17.0 software. We first checked the distribution of data populations with the Shapiro-Wilk W test. 
All the data of the experimental groups exhibited Gaussian distribution. We then performed the 
Levene test for analysis of the homogeneity of variances. The 4 groups in each set of the 4 
experiments were compared by using one-way measures of analysis of variance (ANOVA) followed 
by a Bonferroni post hoc test comparison when equal variances were assumed, or by a Games-
Howell post hoc test comparison when equal variances were not assumed. The null hypothesis was 
rejected when the p level was <0.05, and in such cases the differences were considered significant. 
Data were plotted as means (+ standard error of the mean (SEM)) in the graphs. 
For statistical evaluation of the data in the behavioural tests and histopathology, one-way ANOVA 
was used, followed by Fisher’s LSD post hoc test with StatView 4.53 for Windows software 
(Abacus Concept Inc., Berkeley, CA, USA). These data were expressed as means+SEM. Levels of 
statistical significance in the behavioural tests were taken as p≤0.05 and p≤0.01. 
Measurement of the level of agreement between the two independent histopathologists was 
performed in R Version 3.0.2 with the Cohen κ-test for the different items used to assess the 
morphological changes after partial brain irradiation. This measure calculates the degree of 
agreement in classification over that which would be expected by chance and is scored as a number 
between 0 and 1. A κ value of ≥0.8 indicates excellent, 0.6–0.8 good, 0.4–0.6 moderate, 0.2–0.4 
poor, and <0.2 no agreement. All p values were corrected according to Bonferroni and were 
considered statistically significant if p<0.05. 
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IV. RESULTS 
IV.1. Detection of catecholamines 
We first tested the effects of pre- and post-treatment with SIL on the MPTP-induced significant 
changes in striatal DA ([F(3,29)=10.074, p<0.001, Games-Howell post hoc test: p<0.05]; Figure 3A), 
DOPAC ([F(3,29)=5.45, p<0.05, Bonferroni post hoc test: p<0.05]; Figure 3B) and HVA levels 
([F(3,29)=7.817, p<0.001, Bonferroni post hoc test: p<0.05]; Figure 3C). The SIL treatment did not 
influence these alterations appreciably. In the second set of experiments, we tested the effects of pre- 
and post-treatment with NGN on MPTP toxicity. In this set of experiments, although the NGN 
treatment did not significantly alter the reductions caused in the striatal DA ([F(3,24)=9.552, p<0.001, 
Games-Howell post hoc test: p<0.05]; Figure 3D) and DOPAC ([F(3,24)=10.908, p<0.001, Bonferroni 
post hoc test: p<0.01]; Figure 3E) levels by MPTP administration, a slight lessening of the DA 
decrease was observed. In this experiment, the HVA levels were not altered significantly at all 
(Figure 3F). In the third set of experiments, we tested the effects of pre- and post-treatment with SP 
on the significant MPTP-induced reductions in striatal DA ([F(3,26)=98.189, p<0.001, Bonferroni 
post hoc test: p<0.001]; Figure 3G), DOPAC ([F(3,26)=36.75, p<0.001, Bonferroni post hoc test: 
p<0.001]; Figure 3H) and HVA ([F(3,26)=26.95, p<0.001, Games-Howell post hoc test: p<0.001]; 
Figure 3I) levels. The SP treatment did not influence the MPTP-induced changes, but slightly 
increased the MPTP-caused lethality in mice: 1 of the 10 mice died in the MPTP-treated group, 
whereas 3 died in the SP- and MPTP-co-treated group. In the last set of experiments, we tested the 
effects of pre- and post-treatment with AP on MPTP toxicity. In this set of experiments, MPTP 
administration caused significant reductions in the striatal DA ([F(3,23)=52.339, p<0.001, Games-
Howell post hoc test: p<0.001]; Figure 3J), DOPAC ([F(3,23)=42.98, p<0.001, Bonferroni post hoc 
test: p<0.001]; Figure 3K) and HVA ([F(3,23)=24.54, p<0.001]; Figure 3L) levels as compared with 
the CO values. Although the AP treatment did not influence the MPTP-induced changes 
significantly, it considerably increased the MPTP-caused lethality in mice, as 1 of the 10 mice died 
in each of the AP- and MPTP-treated groups, whereas 7 died in the AP- and MPTP-co-treated group. 
It is also important to mention that none of the tested compounds themselves altered the CO levels 
of DA, DOPAC and HVA. 
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Figure 3. The effects of SIL, NGN, SP and AP treatments on the MPTP-induced decreases in striatal 
DA, DOPAC and HVA concentrations in C57B/6 mice. The treatment with SIL apparently did not 
affect the MPTP-induced reductions in striatal DA (A) and HVA (C) levels, while it abolished the 
significant decrease in DOPAC (B) level. Although NGN treatment slightly, but not significantly 
attenuated the MPTP-induced reduction in striatal DA level (D), it did not alter the change in 
DOPAC level (E), and no significant change in HVA level (F) was observed. SP did not affect the 
MPTP-induced reduction in striatal DA (G), DOPAC (H) or HVA (I) levels. AP did not alter the 
MPTP-induced decreases in striatal DA (J), DOPAC (K) and HVA (L) levels. Data are 
means+SEM; *p<0.05, **p<0.01, ***p<0.001. 
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IV.2. Behavioural performances of animals treated with KYNA analogues 
Four of the newly synthetized KYNA amides were further investigated in behavioural experiments. 
Open-field observations were made on 5 groups of animals: a CO group (injected with saline), and 
KYNA-1, KYNA-2, KYNA-6 or KYNA-11-treated groups. These analogues were chosen for the 
following reasons: KYNA-1 was the only new amide that proved effective as an inhibitor in a 
previous in vitro study, KYNA-2 is structurally very similar to KYNA-1, differing only in 
containing an additional –CH2– group in the side-chain; KYNA-6 and KYNA-11 (KYNA-11, L-
KYN sulphate, was tested earlier by Gigler et al. 2007; Németh et al. 2004) differ appreciably in 
structure not only from each other, but also from KYNA-1 and KYNA-2. 
In acute behavioural experiments, the animals were treated with saline (CO) or KYNA amide 
analogue 2 h prior to the behavioural observations, while chronic treatment was administered on 9 
successive days, with observations on day 9, 2 h after the final injection. The animals treated with 
one or other KYNA amide analogue did not differ greatly in behaviour from those that received the 
saline vehicle. The posture and activity were quite similar in each group. The ambulation time, the 
mean velocity and the number of rearings did not exhibit highly significant differences in most cases 
(Figure 4). Although the ambulation time was somewhat decreased after KYNA-11 administration, 
the changes were not significant (Figure 4A). The mean velocities were nearly the same in each 
group (Figure 4B). Significant changes in performance were observed only in the numbers of 
rearings. Both KYNA-1 and KYNA-11 decreased the number of rearings in the acute experiments, 
and KYNA-11 did so in the chronic experiments too (mean+SEM, p<0.05, p<0.01; Figure 4C). 
Similar behavioural observations were made on rats, but those results are not detailed here. 
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Figure 4. Observations in the open-field arena. (A) Time spent in ambulation. No difference was 
found between the CO and treated groups in either the acute or the chronic experiments. (B) 
Velocity of the movements of the mice. No difference was found between the CO and treated groups 
in either the acute or the chronic experiments. (C) Number of rearings during 5-min observation 
periods. KYNA-1 and KYNA-11 significantly reduced the number of rearings in the acute 
experiments, as did KYNA-11 in the chronic experiments (mean+SEM; *p<0.05, **p<0.01). If not 
labelled, the comparisons were made with the CO group. 
 
IV.3. Results of small-animal irradiation 
The morphological and functional changes were evaluated at dose levels in the range 90–40 Gy: 
outside this dose range, either lethal or serious events (120–100 Gy) or no changes (doses <30 Gy; 
data not reported here) occured during the at most 4-month post-irradiation follow-up period. 
At the highest dose (120 Gy), all of the animals underwent a rapid severe general and 
neurofunctional decline (Figure 5) and died or had to be euthanized between 25 and 40 days after 
the irradiation. The rats irradiated at the 110 Gy dose level survived longer, but also deteriorated 
between 30 and 50 days post-irradiation. At the lower dose levels, there were no signs of a general 
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impairment; the weight gain, eating habits and daily activity did not differ from those of the control 
rats. All the RT animals suffered hair loss from the site corresponding to the beam entrance within 
30 days following the irradiation. 
 
Figure 5. The explorative behaviour of the animals began to diminish 2 weeks after irradiation at 
the 120–110 Gy dose levels, but the rats died before marked changes could occur in this parameter 
(mean+SEM). 
 
IV.3.1. Neurofunctional observations 
In the early monitoring, significant differences in the spontaneous locomotor activity of the rats 
irradiated at 90–40 Gy were not detected with the open-field test (neither in the ambulation time nor 
in the mean velocity), but the motor function began to decline slightly 8 weeks after irradiation with 
the 90 Gy dose. The rearing count was significantly reduced in the groups that received 90–60 Gy. 
The time at which the rearing activity started to diminish was dose-dependent: It was 40–55 days 
post-irradiation after the 90 Gy dose (mean+SEM, p<0.05) (Figure 6). The animals that received 120 
Gy died before marked changes could be seen in this parameter. 
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Figure 6. At the 90 Gy dose level, interesting changes in ambulation ability were detected after 6 
and 8 weeks. The number of rearings also decreased in the 90 Gy group relative to the CO. The 
mean velocity and the immobility time of the rats did not change markedly (mean+SEM; *p<0.05). 
 
The MWM test was found to be a highly sensitive tool for the detection of a neurofunctional 
impairment. A relevant memory deterioration was detected soon after the dose delivery at the 70 Gy 
dose level and the difference increased with time (p<0.001). A significant cognitive deficit was also 
observed 8 weeks after the irradiation in the group treated with 60 Gy (mean+SEM, p<0.05) 
(Figure 7).  
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Figure 7. Memory deterioration was detected 7 days after the dose delivery at the 70 Gy dose level 
and the difference increased with time (mean+SEM; *p<0.05, ***p<0.001). At the 60 Gy dose level, 
a significant cognitive deficit was observed 8 weeks after the irradiation (mean+SEM; *p<0.05). 
 
The commencement of the impairment of the learning-memory function proved to be dose-
dependent; in the groups irradiated at 50–40 Gy, the first sign of deterioration was detected 30 days 
post-irradiation and the difference relative to the CO animals was more pronounced after 90 days 
(Figure 8). 
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Figure 8. In the groups irradiated at 50–40 Gy, the first sign of deterioration was detected 30 days 
post-irradiation and the difference relative to the CO animals was more pronounced after 90 days 
(mean+SEM; ***p<0.001). 
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IV.3.2. MRI findings 
Serial MRI records demonstrated structural damage in the form of cavity formation in the cortical 
region, with extensive perifocal oedema, which generally appeared 2–4 months following irradiation 
(Figure 9). We performed the first post-irradiation MRI after 4 weeks in the majority of the cases, 
since our aim was to investigate late effects. 
120 Gy resulted in a serious deterioration within 4 weeks in all rats. Localized radiation-induced 
cystic necrosis began to appear at approximately 4–8 weeks post-irradiation in one hemisphere of 
rats irradiated with 120–60 Gy; after a lower dose, the structural changes emerged later, 19–24 
weeks after irradiation, in the T1 and T2-weighted (T2W) images of the ipsilateral hemisphere, in 
both the coronal and the sagittal plane (Figure 10). 
 
 
 
Figure 9. MRI revealed visible structural damage in the form of cavity formation in the cortical 
region, with extensive perifocal oedema, which appeared from 2 to 4 months following irradiation. 
Arrows show the site of the radiation injury. T1W AX: the T1-weighted image of the brain in the axial 
plane; T2W SAG: the T2-weighted image of the brain in the sagittal plane. 
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Figure 10. Radiation-induced cystic necrosis began to appear at 4–8 weeks post-irradiation in rats 
irradiated with 120–60 Gy; at lower doses, the structural changes were observed later, 19–24 weeks 
after irradiation, in the T1W and T2W images, in the ipsilateral hemisphere in the coronal plane. 
Arrows show the sites of radiation injury.  
 
IV.3.3. Histopathological evaluations 
No signs of necrosis, i.e. neither reactive gliosis nor any of the other examined histopathological 
categories, were seen on the H&E-stained slides of the CO animals and the non-irradiated regions of 
the brain of the RT animals (Figure 1B). The following parameters correlated closely with the high 
(120–90 Gy), medium (80–60 Gy) or low dose (50–40 Gy) level in the irradiated region of the brain: 
reactive gliosis, vascularization, macrophage density, necrosis and calcification. No significant dose 
dependence was detected as concerns the extent of haemorrhage (Figure 11D). The dose >90 Gy 
groups displayed severe necrosis that reached the grey and white matter, causing severe 
demyelination, with destruction of the fibres. The levels of necrosis, reactive astrogliosis and 
calcification and the density of the foamy macrophages were markedly elevated in these groups as 
compared with the CO animals (Figure 11).  
The extent of the haemorrhage was significantly higher than for the other RT animal groups. The 
scores in the 90 Gy group were as follows: necrosis (2.83), macrophage density (2.33), 
neovascularization (2.50), haemorrhage (1.0), reactive astrogliosis (2.0), calcification (2.17) and 
demyelination (3.0). Severe-to-moderate necrosis was seen in the 80–60 Gy groups, with severe-to-
moderate demyelination, but the fibres could mostly be detected. In comparison with the control 
group, significant correlations were detected in the following categories: necrosis, macrophage 
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density, vascularization, calcification and reactive gliosis. Moderate haemorrhage was observed in 
the animals irradiated with the 80 Gy dose. The scores were as follows: necrosis (1.89), macrophage 
density (2.00), neovascularization (1.89), haemorrhage (1.1), reactive astrogliosis (1.3), calcification 
(1.3) and demyelination (2.2). In the 50–40 Gy groups, mild-to-moderate necrosis was detected, 
with mild-to-moderate demyelination. Significantly increased levels of necrosis, vascularization and 
reactive astrogliosis were seen. Mild calcification occurred. Interestingly, in 1 animal irradiated with 
the 50 Gy dose, meningoencephalitis was observed, but the presence of bacteria was not seen. The 
scores were as follows: necrosis (1.45), macrophage density (1.00), neovascularization (1.00), 
haemorrhage (0.73), reactive astrogliosis (0.73), calcification (0.91) and demyelination (1.27). 
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Figure 11. Dose-related histopathological changes after partial brain irradiation. In the RT region 
of the brain, the degree of necrosis correlated closely with the dose level (mean+SEM, nco=15, 
n40Gy=6, n50Gy=4, n60Gy=3, n70Gy=6, n80Gy=3, n90Gy=6). nco=number of CO rats, nxGy=number of rats 
irradiated at the x Gy dose level. The significance level between the CO and RT groups is indicated 
by *; and the significance level between the 90 Gy group and the remaining RT groups by # (A). The 
numbers of foamy macrophages (B) were significantly elevated relative to the CO animals in all 
groups. A significant correlation was detected in the degree of vascularization in the RT volume 
between the CO and the 90 Gy group (C). Relative to the CO group, the level of haemorrhage was 
significantly increased in all groups except those that received 70 Gy or 40 Gy (D). The degree of 
reactive gliosis was significantly elevated in all the RT groups compared to the CO animals (E). A 
significant correlation was detected in the degree of calcification in the RT volume between the CO 
and the groups irradiated at the 120–90 Gy, 80–60 Gy and 50–40 Gy dose levels (F). The higher 
doses caused severe demyelination, with destruction of the fibres, and the intermediate doses led to 
severe-to-moderate demyelination, while the lower doses resulted in only mild-to-moderate 
demyelination (G). #p<0.05; *p<0.05; ##p<0.01;  **p<0.01; ###p<0.001; ***p<0.001. 
 
IV.4. Treatment with GPC 
 
The 40 Gy RT group exhibited a body weight deficit; their body weight remaining under the normal 
throughout. The difference between the RT and CO groups did not reach the level of statistical 
significance. 
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IV.4.1. MWM test  
The MWM test was used to assess the acquisition and retention of a spatial working memory. 
Healthy rats improve their performance during such place navigation by using their spatial working 
memory. After the 40 Gy irradiation, significant, time-related changes in learning ability were 
detected in both the RT and GPC+RT groups, but these changes were significantly reduced in the 
GPC+RT group (Figure 12). The first sign of deterioration was detected 90 days post-irradiation and 
the difference relative to the CO animals was more pronounced after 120 days (p<0.001). A relevant 
memory impairment was detected in the RT group after 120 days, and a significant cognitive deficit 
was also observed in the GPC+RT group relative to the CO group (p=0.0025). Despite this, there 
was a significant amelioration after GPC management, which reduced the latency of target finding 
relative to the RT group (p=0.012). The GPC ameliorated the memory of the animals and shortened 
the latency time of platform finding. 
 
 
 
 
 
 
 
 
 
Figure 12. Latency of target finding during the MWM test (mean±SEM). Pretreatment with GPC 
decreased the latency time after irradiation, the GPC+RT animals displaying a similar performance 
to that of the CO and GPC groups. The decrease on day 120 was significant (p=0.012). The symbol 
* indicates a significant difference relative to the saline-treated CO group, and the symbol # a 
significant difference relative to the RT group. #p<0.05; **p<0.01; ###p<0.001; ***p<0.001. 
 
IV.4.2. Histopathology 
The H&E-stained slides of the CO animals and the non-irradiated regions of the brain of the treated 
animals exhibited no signs of necrosis, i.e. neither reactive astrogliosis, nor any of the other 
examined histopathological categories. In the irradiated region of the brain, the following parameters 
correlated closely with the 40 Gy dose level: necrosis, macrophage density, reactive gliosis, 
calcification and demyelination.  The RT group displayed moderate necrosis that reached the grey 
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and white matter, causing demyelination, with destruction of the fibres. The grades of reactive 
astrogliosis and calcification, the density of the foamy macrophages and the degree of demyelination 
were all significantly elevated in the RT group as compared with the CO animals. Marked protective 
effects of GPC were detected as concerns the macrophage density (p<0.001), reactive astrogliosis 
(p<0.001), calcification (p=0.012) and the extent of demyelination (p=0.035). The scores in the RT 
group were as follows: necrosis 3.33, macrophage density 2.83, reactive astrogliosis 3.50, 
calcification 3.0 and demyelination 3.17. In the GPC+RT group, mild-to-moderate necrosis was seen, 
with mild-to-moderate demyelination, but the fibres could mostly be detected. In comparison with 
the CO group, significant correlations were detected in the following categories: necrosis, 
macrophage density, reactive gliosis, calcification (Figure 13) and demyelination (Figure 14). The 
scores were as follows: necrosis 2.33, macrophage density 1.50, reactive astrogliosis 1.83, 
calcification 2.0 and demyelination 2.17 (Figure 15).  
 
Figure 13. As expected, the degree of calcification after 120 days was markedly higher in the RT 
group than in the CO group, and the GPC treatment protected the brain tissue from this effect 
(mean±SEM, p=0.013). The symbol * indicates a significant difference between the CO and RT 
groups; and the symbol # indicates a significant difference between the RT and the other groups. 
#p<0.05; *p<0.05; ###p<0.001; ***p<0.001. 
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Figure 14. The level of demyelination after 120 days was significantly higher in the RT group as 
compared with the CO animals, while GPC exerted a marked protective effect (mean±SEM, 
p=0.034). The score in the RT group was 3.17. In the GPC+RT group, mild-to-moderate 
demyelination was seen, but the fibres could mostly be detected. The symbol * indicates a significant 
difference between the CO and RT groups; and the symbol # indicates a significant difference 
between the RT and the other groups. #p<0.05; *p<0.05; ###p<0.001; ***p<0.001. 
 
 
 
 
 
 
 
Figure 15. Light micrographs of the hippocampal region in the non-irradiated CO group of rats. 
Histopathological changes of the hippocampus in response to irradiation and administration of 
GPC (A). RT group: severe necrosis that reached the grey and white matter, causing demyelination, 
with destruction of the fibres (B). The GPC-treated group was similar to the sham-irradiated group 
(C). In the GPC+RT group, marked protective effects of GPC were detected as concerns the 
macrophage density, reactive astrogliosis, calcification and the extent of demyelination. Only focal 
haemorrhage was noted (D). Scale bar: 200 µm. 
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V. DISCUSSION 
The role of MRPs in the MPTP-induced neurotoxicity 
There is increasing evidence supporting the roles of BBB and BCSFB dysfunctions in 
neurodegeneration, including PD. Although the alteration in P-gp-mediated transport has been 
demonstrated to play a central role in the neurodegenerative process (Drozdzik et al. 2003), only a 
few data are available on the involvement of MRPs in PD. The aim of our study was therefore to 
assess the effects of certain compounds which can modulate the function of MRPs expressed on the 
BBB and BCSFB (MRP1, 2, 4 and 5) on MPTP toxicity in C57B/6 mice. Two of these compounds, 
SIL and NGN, are well-known flavonoids (most of these compounds have potent antioxidant and 
free radical scavenging properties) (Ross & Kasum 2002), which have already been tested in certain 
toxin models of PD, but not in the MPTP model. SIL, which is known to exert complex 
pharmacological action (Saller et al. 2007) including MRP inhibitor properties, is capable of the 
attenuation of maneb- and paraquat-induced lipid peroxidation (Singhal et al. 2011). However, in 
our study SIL did not alter MPTP-induced neurotoxicity. The reason for this difference would be 
that maneb and paraquat were applied in a chronic treatment regime twice a week for 9 weeks, 
which presumably caused less harm than that in the widely applied acute MPTP model. The other 
flavonoid, NGN, with MRP1, MRP2 and MRP4 stimulator properties, was moderately protective 
against 6-hydroxy-DA-induced neurotoxicity as it significantly attenuated the loss of DAergic 
neurones and the decrease in striatal DA levels (Zbarsky et al. 2005). Accordingly, in our study 
NGN treatment caused a slight, but not significant preservation of striatal DA content. In contrast 
with the above flavonoids, the effects of SP have not been tested in toxin models of PD. Although it 
did not appear to affect the striatal DA concentrations in our study, it slightly increased the MPTP-
caused lethality in C57B/6 mice. It should be mentioned here that SP can reduce serum urate levels 
through its uricosuric effect. In a previous study, oral high-dose administration of the xanthine 
oxidase inhibitor and MRP4 stimulator AP resulted in a decreased level of urate, which may have an 
important role in the neuronal antioxidant pool in the striatum, but did not affect the DA level in rats 
(Miele et al. 1995; Desole et al. 1996). Accordingly, in our study AP considerably enhanced the 
MPTP-caused lethality, but the striatal DA content was preserved in the survivors. The main 
explanation for the potentiation of MPTP toxicity by AP would be the decrease of urate 
concentration by the inhibition of xanthine oxidase. However, an enhanced transport by MRP4 
would also accompany the depletion of urate. Hence, a decrease in serum urate level would 
accompany the progression of PD (Sun et al. 2012). 
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The depletion of striatal urate by AP (which could be enhanced by its MRP4 stimulatory 
effect) or the use of probenecid (with MRP1 and 5 and organic acid transporter inhibitory and 
uricosuric effects) clearly augmented MPTP toxicity in C57B/6 mice, while SP (with MRP1, 4 and 5 
inhibitory, MRP2 stimulatory and uricosuric effects) only slightly augmented MPTP-induced 
neurotoxicity. On the other hand, a mild level of prevention of the DA decrease was observed in 
mice treated with one flavonoid, NGN (with MRP1, 2 and 4 stimulatory effects), but no influence by 
another flavonoid, SIL (with MRP1, 2, 4 and 5 inhibitory effects). In conclusion, these data indicate 
that the depletion of urate augmented by MRP4 stimulation increases, while the stimulation of 
MRP1- or 2-mediated transporters (probably GSH-conjugated toxic substances) slightly attenuated 
MPTP-induced neurotoxicity. 
 
Effects of some KYNA analogues 
It was important that KYNA-1, which had proved neuroprotective in several models (Vámos 
et al. 2009; Marosi et al. 2010; Németh et al. 2006; Knyihar-Csillik et al. 2008), and partially 
inhibited NMDA-mediated synaptical transmission in the hippocampus, did not induce significant 
changes in the behaviour of the tested animals. The results confirmed that none of the studied 
KYNA derivatives induced major changes in the behaviour of these animals. Only the number of 
rearings was reduced somewhat after KYNA-1 or KYNA-11 administration. Moreover, as KYNA-1 
did not significantly influence the behavioural performance in the open-field arena, KYNA-1 
treatment does not appear to have any appreciable side-effects. 
 
Focal rat brain irradiation model   
A simple and effective method was developed for the delivery of a radiation dose to a well-
defined area in one hemisphere of the brain, including the hippocampus and corpus callosum, in rats, 
similarly to human brain tumour radiotherapy, as recommended by others (Kalm et al 2013). It 
allows the investigation of a maximum of 6 small animals simultaneously and comprises a 
reproducible experimental model for quantification of the functional and morphological changes 
occurring due to radiation-induced focal brain damage within a reasonable time frame. Preclinical 
studies on CNS injuries have mainly made use of non-targeted dose delivery resulting from whole-
body radiation fields with the selective shielding of extracranial parts (Akiyama et al. 2001, 
Vinchon-Petit et al. 2010), or whole-brain irradiation using a standard field with a bolus above the 
skull (Ernst-Stecken et al. 2007). However, highly selective dose delivery techniques were recently 
introduced for humans in the cases of head and neck and primary brain tumours. For radiobiological 
investigations in an experimental setting corresponding to clinical radiotherapy, conformal partial 
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brain irradiation has been performed on large animals (Tiller-Borcich et al. 1987, Lunsford et al. 
1990, Yamaguchi et al. 1991, Spiegelmann et al. 1993), or a sophisticated technique, such as small 
animal stereotactic irradiation either with a gamma knife (Yang et al. 2000, Kamiryo et al. 2001, 
Liscák et al. 2002, Jirák et al. 2007, Liang et al. 2008, Charest et al. 2009, Hirano et al. 2009, 
Massager et al. 2009a, 2009b, Marcelin et al. 2010) or with a linear accelerator (LINAC)-based 
approach (Ernst-Stecken et al. 2007). Arc therapy with the application of cylindrical collimators 
allows the irradiation of subregions of the skull of one subject animal (Reinacher et al. 1999, Münter 
et al. 2001) and the addition of image guidance of cone beam CT results in increased accuracy (Tan 
et al. 2011). We performed a dose-de-escalation from 120–40 Gy in 10 Gy steps. The morphological 
and functional changes detected were clearly related to the radiation dose. The 2-weekly assessment 
of open-field tests did not reveal any behavioural alteration, apart from the rats irradiated at 120–110 
Gy, which displayed an obvious deterioration. Only the changes in rearing activity indicated the 
effects of the focal brain injury; these were first observed 40–55 days post-irradiation at the 90 Gy 
dose level. In the course of its explorations, the rat gains information about its environment, and it 
continues this activity until it can develop an integrated concept of the situation. One of the most 
important roles of the hippocampus is to achieve this integration, and in normal rats this proceeds 
well. Rats with an impaired dorsal hippocampus require more extensive exploration to attain the 
same result. The changes in spontaneous locomotor activity mostly depend on the nature and 
magnitude of the lesions (Leggio et al. 2006, Alstott et al. 2009). In our experiments, the slight 
changes in locomotor activity can be explained by the short time frame of the open-field tests. These 
revealed that the effects of relevant damage in the motor cortex start to become observable 8 weeks 
after irradiation, which corresponds well to the development of an irreversible human focal brain 
injury (Godsil et al. 2005, Huang et al. 2009, Caceres et al. 2010). Nevertheless, we do not consider 
the open-field activity to be a highly sensitive tool for the detection of changes due to radiation 
damage. A subsequent detailed analysis of our data demonstrated that the locomotor deterioration 
could be measured at high dose levels and at later time points than 2 months after the treatment. In 
planned studies, therefore, we intended to perform open-field tests at 2-week intervals up to 6 
months. The MWM test is widely used for the detection of neurofunctional impairments (Justino et 
al. 1997, Yoneoka et al. 1999, Akiyama et al. 2001, Liscák et al. 2002, Vorhees & Williams 2006, 
Jirák et al. 2007, Shi et al. 2011). In our model, the memory decline first appeared between 30 and 
120 days after the irradiation, clearly depending on the dose delivered. The behavioural impairment 
correlated closely with the morphological changes detected by MRI and histology. Numerous 
publications have described different methods and reported on the value of MRI examinations for 
the detection of changes (even at a molecular level) due to ionizing radiation in a small-animal brain. 
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The radiation-induced morphological changes demonstrated by repeated MRI scans correlated well 
with the dose, the duration and location of the lesion (Karger et al. 1997, Ishikawa et al. 1999, 
Brisman et al. 2003). Single doses of 150 Gy or 100 Gy produced necrosis in the hippocampus 
within 1–3 months (Liscák et al. 2002) and 75 Gy caused a focal brain lesion within 3–6 months 
(Liscák et al. 2002, Jirák et al. 2007). At doses higher than 60 Gy, necrotic changes started to appear 
within 6 months (Liscák et al. 2002, Brisman et al. 2003), and 20 months after lower doses, such as 
25–50 Gy, delivered to the right frontal lobe of rats, MRI changes were demonstrated in relaxation 
times T1 and T2 (Karger et al. 1997, Ishikawa et al. 1999). We set out to perform simultaneous MRI 
examinations on 6 rats with the available 1.5 T device and a human brain coil in order to detect and 
follow up the necrotic changes in vivo, and to optimize the time point of histopathologic 
examinations. Our method proved simple and effective, with a relatively high throughput, and the 
results exhibited a clear correspondence with the histopathological findings. The H&E slides 
showed that the irradiation was localized to a defined small brain volume and the effects in the 
animals were well reproducible: the damage appeared only in the irradiated region. We did not 
observe histopathological aberrations in the contralateral hemisphere or in the control animals. This 
proves the efficacy of the irradiation method. The induced changes depended strongly on the 
radiation dose. 
Significant correlations were detected between the radiation dose and the degree of necrosis, 
the presence of foamy macrophages, the vascularization and the calcification. Previous studies have 
indicated that histopathological structural changes involving a decrease in the cell number and 
demyelination can be expected in the dose range 50–100 Gy (Kamiryo et al. 2001, Liscák et al. 2002, 
Ernst-Stecken et al. 2007). With such doses, our histopathological analysis revealed measurable 6 x 
8 mm necrotic lesions with cysta ex emollition, haemorrhage and a reactive cellular response. In 
confirmation of earlier data (Münter et al. 1999, Liscák et al. 2002, Jirák et al. 2007, Kumar et al. 
2012), the severity of the radiation damage was strictly dose-dependent. 
 
Testing radiation injury and potential radiation modifiers 
The various new radiation techniques encourage escalation of the dose in the treatment of primary 
and secondary brain tumours, though this is accompanied by an increase in the probability of 
complications in the healthy regions of the brain, while the concurrent chemotherapy applied in 
cases of glioblastoma results in a rise in the number of treatment-related injuries (Brandsma et al. 
2008; Chamberlain et al. 2007; de Wit et al. 2004). On the other hand, the rising number of cases of 
human stereotactic radiosurgery (SRS) in which a single dose of 18–26 Gy is applied verify the 
clinical relevance of investigations on single dose delivery. In clinical series of SRS, the 
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development of brain necrosis has been reported with probabilities of 25–40%. If the level of 
cognitive reduction could be lessened, the QOL of the survivors would improve and the social and 
economic strain would be reduced. There is therefore a great need for a potent radioprotector which 
could decrease the extent of damage to the healthy brain.  
The hippocampus is the major brain area that plays a crucial role in the processes of learning and 
memory (Izquierdo & Medina 1997; Gil-Mohapel et al. 2013), and numerous data clearly confirm 
that irradiation causes a deterioration of these functions (Rola et al. 2004; Raber 2010; 
Yazlovitskaya et al. 2006). In the hippocampus, the dentate gyrus is the region most susceptible to 
radiation (Monje 2008), because this is the site of neurogenesis (Monje & Palmer 2003; Zhao et al. 
2008). Our earlier study of the dose–response relationship indicated that the chosen model is 
relevant for studying various aspects of healthy brain protection (Hideghéty et al. 2013).  
In our present investigation, this method revealed a promising ameliorative effect of GPC, which 
can be explained by its role in preserving the cell membranes and cognitive functions in the CNS. 
Choline and choline-containing phospholipids such as GPC display mainly a cholinergic profile, 
interfering with phospholipids biosynthesis, brain metabolism and neurotransmitter systems, and are 
responsible for maintaining the cell membrane integrity and are also precursors of the 
neurotransmitter acetylcholine, which is involved in a number of brain processes, including learning 
and memory (Tayebati et al. 2013). GPC has previously been studied as a centrally acting 
parasympathomimetic drug in acute cerebrovascular diseases and dementia disorders (Barbagallo 
Sangiorgi et al. 1994; Parnetti et al. 2001). After oral administration, GPC can cross the BBB and 
reach the CNS, where it can exert beneficial effects in the treatment of the sequelae of cognitive 
disorders and cerebrovascular accidents. It can incorporate into the phospholipid fraction of the 
neuronal plasma membrane and can also increase the levels of production and release of 
acetylcholine in the brain (Amenta & Tayebati 2008; Tayebati et al. 2011; Tayebati et al. 2013). A 
trial of the clinical efficacy and tolerability of GPC on 2044 patients after stroke or transient 
ischaemic attacks confirmed the therapeutic efficacy of GPC in the cognitive recovery, the presumed 
mechanism involving the provision of a high level of choline for the nervous cells, which protects 
their cell membranes (Barbagallo Sangiorgi et al. 1994). 
Our study clearly illustrates the protective effects of GPC at both functional and morphological 
levels. The cognitive dysfunction resulting from irradiation can be examined by different methods. 
The MWM has been found to be a highly sensitive tool for the detection of a neurofunctional 
impairment (Akiyama et al. 2001; Jirák et al. 2007; Justino et al. 1997; Liscák et al. 2002; Shi et al. 
2011; Vorhees & Williams 2006; Yoneoka et al. 1999). The MWM task clearly demonstrated the 
effects of GPC on the working memory and long-lasting reference memory of rats after irradiation at 
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a 40 Gy dose level, the differences in learning ability between the RT and CO groups becoming 
more pronounced as time passed.  
An earlier analysis of the histological changes led to the finding that brain irradiation modified the 
spine density and also the proportions of the morphological subtypes in the dendrites of the dentate 
gyrus granule cells and the basal dendrites of the CA1 pyramidal neurones, in a time-dependent 
manner (Chakraborti et al. 2012). Pathological disturbances such as vascular damage and 
demyelination are late consequences of irradiation that are likewise revealed by histological 
examination (Brown et al. 2005). The primary targets of radiation damage include the 
oligodendrocytes and the white matter, which suffer necrosis (Shen et al. 2012; Valk & Dillon 
1991). In our study, the levels of such histopathological deterioration, scored semiquantitatively, 
were ameliorated significantly by GPC treatment. The changes in cognitive ability correlated closely 
with the histopathological findings indicative of the radio-neuroprotecive action of GPC. 
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VI. CONCLUSIONS AND FINDINGS 
The investigation of the potential neuroprotectors resulted in the exclusion of the MRP 
approach from further research and warranted the performance of further preclinical examinations 
on the kynurenine pathway and with phosphatidylcholine derivatives.  
We have carefully examined numerous MRP inhibitors/stimulators, which did not 
significantly influence the striatal levels of DA and its metabolites. Although, NGN mildly mitigated 
the DA level reduction, this did not reach the level of significance.  
We experienced the opposite effect of AP, which considerably intensified the MPTP-induced 
lethality. The possible explanation of these findings could involve stimulation of the MRP1- and 
MRP2-mediated transport of the protective GSH conjugates which act against toxic agents, or 
possibly the enhancement of the oxidative stress caused by the MRP4-mediated efflux of brain uric 
acid, which has marked antioxidant activity.  
Our next approach to achieve a protective effect in the CNS was the use of different 
analogues that play key roles in the kynurenine pathway. The analysis of several KYNA analogues 
provided a growing body of data concerning the effects of these compounds in mouse models. Our 
experiments proved the good tolerability of these agents, without notable toxic effects. These agents 
could therefore be examined in our newly-developed small-animal model. 
Within the neurofunctional examinations on drug tolerability, particularly the value of an 
open-field task could be demonstrated in investigations of locomotor activity and explorative 
behaviour. 
The partial rat brain irradiation technique that we have developed with the human 
stereotactic BrainLab system, provides a high-precision, single dose delivery at the same time to 2 
animals. It causes a pronounced brain injury in a predetermined volume.  
We have also developed a well-reproducible small-animal radiation model for 6 rats that 
results in dose-dependent focal brain damage limited to one hemisphere.  
In addition, a complex and reliable system of examinations on functional and morphological 
alterations was developed with which the radiation-induced late changes in the CNS could be 
followed in a small-animal model appropriate for investigations on radiation modifiers.  
We have derived a dose–effect curve of radiosensitivity via the MWM test, exhibiting the 
effects of differences between 10 Gy dose levels. The MWM test proved to be the most sensitive 
method among the neurofunctional examinations.  
Our data have provided experimental evidence of the changes in cognitive function and histological 
deterioration after the irradiation of one hemispherical hippocampus and the potential for GPC 
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treatment to exert a favourable influence on such events. This study warrants further research on the 
protective or mitigating effects of GPC on radiation injuries.  
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EGYETEMI DOKTORI ÉRTEKEZÉS – MAGYAR NYELVŰ ÖSSZEFOGLALÓ 
 
Kutatásaink középpontjában a neurodegeneratív folyamatok, a sugárzás-indukálta agyi 
károsodások, illetve ezek esetleges kivédésének kisállat modellekben történő vizsgálata áll. A 
neurodegeneratív betegségeknek és a sugárzás-indukálta agyi károsodásoknak számos közös 
jellemzője van. A sugárzás hatására kialakuló szövettani és sejtszintű elváltozások jelentős 
mértékben hasonlítanak a neurodegeneratív folyamatok eredményeként manifesztálódó 
neurodestruktív elváltozásokhoz, sejtpusztuláshoz. Mindkettőre igaz tehát a progresszív 
neuronpusztulás, a motoros és kognitív funkcióbeli hanyatlás. Hasonlóság van, a következményként 
megjelenő, különböző mértékű gyulladásos folyamatok előfordulásában is. A neuronpusztulás 
kezdetétől az első, egyértelmű klinikai tünetek megjelenéséig általában évek, évtizedek telnek el, 
amely idő alatt a sejtek túlnyomú többsége érintetté válik.  
A Parkinson-kór (PK) egy progresszív jellegű neurodegeneratív kórkép, amelyben a 
substantia nigra pars compacta (SNpc) dopaminerg idegsejtjeinek pusztulása figyelhető meg. A 
mitokondriális komplex I szelektív gátlásával lehetségessé válik a PK állatkísérletes előidézése. Erre 
alkalmas vegyület az 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), amit a gliális 
monoaminooxidáz 1-methyl-4-phenylpyridiniummá (MPP+) alakít, amely a dopamin transzporteren 
keresztül képes a SNpc dopaminerg sejtjeibe jutni, és itt a légzési lánc I-es komplexének működését 
gátolni. A légzési lánc gátlásának eredménye megnövekedett szabadgyök képződés, illetve ATP 
depléció, ami rövid időn belül sejtpusztuláshoz vezet.  
A központi idegrendszeri tumorok incidenciája folyamatosan növekszik, a sugárkezelés a 
standard komplex terápia elengedhetetlen része mind primer, mind szekunder, azaz metasztatikus 
agytumorok esetén. Az agy radiogen nekrózisa a malignus tumorok miatt végzett sugárkezelés 
súlyos, jelenleg nem kezelhető, irreverzibilis szövődménye, az agresszív malignus központi 
idegrendszeri tumorok hatékony sugárkezelésének akadálya. A tumort nagy valószínűséggel 
elpusztító dózis az agy, ill. a gerincvelő viszonylagosan alacsony sugár-toleranciája miatt nem 
adható le. Amennyiben hatékony neuroprotektív gyógyszer állna rendelkezésünkre, a terápiás index 
(tumor ellenes hatás/mellékhatás arány) lényegesen javítható lenne.     
 A központi idegrendszerben a triptofán oxidatív metabolizmusa során keletkező metabolitok 
megváltoztatják az agyszövet excitabilitását. Azok a szerek, amelyek gátolják a glutamátreceptor-
agonista metabolitok (kvinolinsav), valamint a szabadgyök-generált hatásokat, potenciálisan 
neuroprotektív hatásúak lehetnek. A kinurénsav (KYNA) N-metil-D-aszpartát (NMDA)-
receptorokon antagonista hatást fejt ki, így csökkenti a szabadgyök-képződés révén indukált 
neurotoxikus hatást, amely elsősorban a neocortexben, a striatumban és a hippocampusban alakul ki. 
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Ezek a régiók a neurodegeneratív betegségek (pl. Alzheimer-kór, Parkinsor-kór) predilekciós areái. 
A KYNA elő-anyaga, az L-kinurenin valamint bizonyos KYNA származékok átjutnak a vér-agy 
gáton. Ezen vegyületek hatékonyan képesek gátolni az agyi sérüléseket követő hiperexcitációt, 
ezáltal megfelelő koncentrációban neuroprotektív hatásúak, melyet különböző noxák okozta 
károsodás csökkentésében sikerült bizonyítani. Fontosak azok a kísérletes eredmények is, amelyek 
arra utalnak, hogy a kinureninek és metabolitjaik befolyásolják az agyi véráramlást: vazodilatációs 
hatásuk segítheti a neuroprotektív folyamatokat.  
Kísérleteink célja az volt, hogy olyan reprodukálható, preklinikai állatmodelleket 
tervezzünk és alkalmazzunk, amelyek segítségével a különféle neurotoxikus ágensek által 
kiváltott károsodások kivédésére alkalmas összetevőket tesztelhetünk. Célul tűztük ki az 
ígéretesnek tűnő neuroprotektív anyagok tolerabilitásának és esetleges toxikus hatásainak 
meghatározását. Célunk volt bizonyos multidrug rezisztencia-asszociált fehérjék (MRP1, 2, 4 és 
5) szerepének vizsgálata az MPTP által kiváltott neurotoxicitásban. Továbbá, hogy a KYNA 
amidok viselkedésre gyakorolt mellékhatásait vizsgáljuk meg C57B/6 egértörzsben. Célul tűztük 
ki az ionizáló sugárzás hatására kialakuló korai, és késői elváltozások összefüggéseinek 
viselkedésbeli, makro- és mikromorfológiai tanulmányozását, valamint a károsodás 
mechanizmusának befolyásolásával potenciális radio-neuroprotektív anyagok preklinikai 
vizsgálatát, melyek a későbbiekben alkalmasak lehetnek a klinikai gyakorlatban való kipróbálásra 
is. 
C57B/6 egerekben az MPTP akut modellben történő alkalmazását megelőzően és azt 
követően egy héttel naponta intraperitonealisan alkalmazott szilimarin, naringenin, szulfinpirazon és 
allopurinol kezelést követően nagy teljesítményű folyadékkromatográfiával mértük a striatalis 
dopamin, 3,4-dihidroxifenilecetsav és homovanillinsav szinteket. A tesztelt MRP 
inhibítorok/stimulátorok közül egyik sem befolyásolta szignifikáns mértékben a dopamin és 
dopaminmetabolitok striatalis szintjét, azonban a naringenin kismértékben mérsékelte a 
dopaminszint csökkenését, míg az allopurinol nagymértékben fokozta az MPTP okozta letalitást. 
Ezen eredmények magyarázata egyrészt a toxikus anyagok glutation-konjugátumainak MRP1- és 
MRP2-mediálta transzportjának stimulálása által kiváltott jótékony hatás, másrészt az agyi urát, 
amely jelentős antioxidáns hatással rendelkezik, MRP4-mediálta effluxa miatt az oxidatív stressz 
fokozódása lehet. 
Számos KYNA analóg tesztelése folyt, melynek segítségével egyre több adatunk lett ezen 
anyagok hatásáról. Nem tapasztaltuk markáns toxikus hatásukat egerekben sem.  
Az általunk kialakított patkány rész-agy besugárzási technika humán sztereotaktikus 
BrainLab rendszerben, nagy pontosságú, egyszeri dózisleadást biztosít egyidejűleg két állat számára, 
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kifejezett agyi károsodást okozva az előre meghatározott térfogatban. Ezt követően kis volumenű 
rész-agy besugárzás történt 10 mm-es foton kollimátor kiöntése után 6 MeV energiájú elektron 
mezőkkel egyszerre 6 állaton. Két laterális opponáló mezővel kétoldali patkány hippocampus 
homogén besugárzását követő akut és krónikus hatások vizsgálatát végeztük. Ez a módszer jól 
alkalmazható a sugárhatás kísérletes tanulmányozására.  
Az MR vizsgálat lehetővé tette az agyi strukturális károsodások megjelenésének noninvazív 
vizualizálását, és a besugárzási dózis–hatás vizsgálatát. Ennek alátámasztására szolgáltak a 
neurofunkcionális tesztek, majd végül a szövettani vizsgálatok. Eredményeink igazolják a fokális 
agyi besugárzást követő kognitív funkcióbeli, illetve szövettani szintű elváltozások kialakulását, 
valamint az L-alpha glycerylphosphorylcholine (GPC) kezelés fenti károsodásokra gyakorolt 
kedvező hatását.  
  
 
 
